Brain Cancer Clinical Trials

Showing 1341-1360 of 1,466 trials

Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors

NCT00100880

This phase I trial is studying the side effects and best dose of lenalidomide in treating young patients with recurrent, progressive, or refractory CNS tumors. Lenalidomide may stop the growth of CNS tumors by blocking blood flow to the tumor. It may also stimulate the immune system in different ways and stop tumor cells from growing.

Childhood Atypical Teratoid/Rhabdoid TumorChildhood Central Nervous System Germ Cell TumorChildhood Choroid Plexus Tumor+23 more

National Cancer Institute (NCI)45 participantsStarted Nov 2004

Memphis, Tennessee, United States

COMPLETEDPhase 1

Cilengitide in Treating Children With Refractory Primary Brain Tumors

NCT00063973

This phase I trial is studying the side effects and best dose of cilengitide in treating children with recurrent, progressive, or refractory primary CNS tumors. Cilengitide may slow the growth of brain cancer cells by stopping blood flow to the tumor.

Childhood Central Nervous System Germ Cell TumorChildhood Choroid Plexus TumorChildhood Craniopharyngioma+23 more

National Cancer Institute (NCI)24 participantsStarted Jul 2003

Memphis, Tennessee, United States

Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors

Cilengitide in Treating Children With Refractory Primary Brain Tumors

Related Searches

Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme

Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors

AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme

Prevalence of Post-craniotomy Headache in Siriraj Hospital

Tolerability Study of Xerecept® in Pediatric Patients

A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma

Markers of Prognosis and Response to Therapy in Patients With Metastatic Brain Tumors Undergoing Stereotactic Radiosurgery (SRS)

Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas

Dose Escalation Study of Vandetanib With Hypofractionated Stereotactic Radiotherapy in Recurrent Malignant Gliomas

Hypertension Monitoring in Glioma Patients Treated With Bevacizumab

Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma

Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors

Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors

Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas

Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Intraoperative MRI and 5-ALA Guidance to Improve the Extent of Resection in Brain Tumor Surgery

Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer